CD274 and neoplasm: A Phase II study completed in 2017 investigated neoadjuvant nivolumab in 30 primary or recurrent GBM patients with a primary outcome of percent change in PD-L1 expression in tumor cells and lymphocytes following neoadjuvant nivolumab [127].